Is Moderna Finally Ready To Make A ‘Big Commitment’ On Not-For-Profit COVID-19 Vaccines?
Last Company To Pledge
Some countries want an IP waiver to boost access to vaccines, but industry leaders say this will do nothing to increase output.
You may also be interested in...
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
Once expected to play a key role in beating COVID-19, Sanofi and GSK now see their vaccine as most likely to be used as a booster.
Promising early-stage data from two companies looking to break into crowded hemato-oncology markets.